Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis

Joint Bone Spine

Volumn 78, Issue 4, 2011, Pages 341-346

  Botzoris, Vasileios ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Digital ulcers; Management; Raynaud's phenomenon; Systemic sclerosis; Vasculopathy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AUTOANTIBODY; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLOPIDOGREL; CYCLIC GMP; DILTIAZEM; DIPYRIDAMOLE; FLUOXETINE; GLYCERYL TRINITRATE; ILOPROST; LOSARTAN; LOW MOLECULAR WEIGHT HEPARIN; NIFEDIPINE; OPC 28326; PENTOXIFYLLINE; PRAZOSIN; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CAPILLAROSCOPY; CAPILLARY FLOW; CELL ACTIVATION; CLINICAL FEATURE; CLOTHING; COLD EXPOSURE; COLOR ULTRASOUND FLOWMETRY; DIGITAL ULCER; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DOPPLER FLOWMETRY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DYSPHAGIA; DYSPNEA; FAMILY HISTORY; FLUSHING; GANGRENE; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MENTAL STRESS; MULTICENTER STUDY (TOPIC); ONSET AGE; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; SKIN TEMPERATURE; SMOKING CESSATION; SUSTAINED DRUG RELEASE; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; ULCER;

CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; ENZYME INHIBITORS; FINGERS; HUMANS; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS I; RAYNAUD DISEASE; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONAMIDES; VASODILATOR AGENTS;

EID: 79960645284     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.11.005     Document Type: Short Survey

References (60)

1. LeRoy E.C., Medsger T.A. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992, 10:485-488.
2. Skopouli F.N., Talal A., Galanopoulou V., et al. Raynaud's phenomenon in primary Sjögren's syndrome. J Rheumatol 1990, 17:618-620.
3. Allanore Y., Avouac J., Kahan A. Systemic sclerosis: an update in 2008. Joint Bone Spine 2008, 75:650-655.
4. Denton C.P., Korn J.H. Digital ulceration and critical digital ischaemia in scleroderma. Scleroderma Care Res 2003, 1:12-16.
5. Voulgari P.V., Alamanos Y., Papazisi D., et al. Prevalence of Raynaud's phenomenon in a healthy Greek population. Ann Rheum Dis 2000, 59:206-210.
6. Cutolo M., Pizzorni C., Secchi M.E., et al. Best Pract Res Clin Rheumatol 2008, 22:1093-1108.
7. Maricq H.R. Wide-field capillary microscopy. Arthritis Rheum 1981, 24:1159-1165.
8. Lonzetti L.S., Joyal F., Raynauld J.P., et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001, 44:735-736.
9. Sebastiani M., Manfredi A., Colaci M., et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 2009, 61:688-694.
10. Schmidt W.A., Krause A., Schicke B., et al. Color Doppler ultrasonography of hand and finger arteries to differentiate primary from secondary forms of Raynaud's phenomenon. J Rheumatol 2008, 35:1591-1598.
11. Hasegawa M., Nagai Y., Tamura A., et al. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 2006, 155:1159-1164.
12. Connell D.A., Koulouris G., Thorn D.A., et al. Contrast-enhanced MR angiography of the hand. Radiographics 2002, 22:583-599.
13. Oddis C.V., Eisenbeis C.H., Reidbord H.E., et al. Vasculitis in systemic sclerosis: association with Sjögren's syndrome and the CREST syndrome variant. J Rheumatol 1987, 14:942-948.
14. Shapiro L.S. Large vessel arterial thrombosis in systemic sclerosis associated with antiphospholipid antibodies. J Rheumatol 1990, 17:685-688.
15. Clark S., Dunn G., Moore T., et al. Comparison of thermography and laser Doppler imaging in the assessment of Raynaud's phenomenon. Microvascular Res 2003, 66:73-76.
16. Murray A.K., Moore T.L., King T.A., et al. Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. Arthritis Rheum 2006, 54:1952-1960.
17. Korn J.H. Scleroderma: a treatable disease. Cleve Clin J Med 2003, 70:954. [956, 958 passim.].
18. Opie L.H., Yusuf S., Kübler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog Cardiovasc Dis 2000, 43:171-196.
19. Thompson A.E., Shea B., Welch V., et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001, 44:1841-1847.
20. Thompson A.E., Pope J.E. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 2005, 44:145-150.
21. [No authors listed]. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000;160:1101-8.
22. Rademaker M., Cooke E.D., Almond N.E., et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989, 298:561-564.
23. Dziadzio M., Denton C.P., Smith R., et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999, 42:2646-2655.
24. Gliddon A.E., Doré C.J., Black C.M., et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007, 56:3837-3846.
25. Pope J, Fenlon D, Thompson A, et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000;(2):CD000956.
26. Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study Arthritis Rheum 2004;50:3994-4001.
27. Coleiro B., Marshall S.E., Denton C.P., et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001, 40:1038-1043.
28. Teh L.S., Manning J., Moore T., et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 1995, 34:636-641.
29. Franks A.G. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet 1982, 1:76-77.
30. Cheung G.T.Y., Lau C.S., Kumana C.R. Phosphodiesterase 5-inhibitors relieve symptoms of severe Raynaud's phenomenon. Ann Rheum Dis 2004, 64(Suppl. 2):21.
31. Colglazier C.L., Sutej P.G., O'Rourke K.S. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol 2005, 32:2440-2442.
32. Gore J., Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005, 64:1387.
33. Fries R., Shariat K., von Wilmowsky H., et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005, 112:2980-2985.
34. Caglayan E., Huntgeburth M., Karasch T., et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006, 166:231-233.
35. Sandorfi N., Jimenez S.A. Treatment of digital ulceration due to Raynaud's phenomenon (RP) with long acting phosphodiesterase 5 (PDE5) inhibitor: tadalafil. Ann Rheum Dis 2007, 66(Suppl. 2):223.
36. Schiopu E., Hsu V.M., Impens A.J., et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009, 36:2264-2268.
37. Brueckner C.S., Becker M.O., Kroencke T., et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010, 69:1475-1478.
38. Fishman A.P. Pulmonary hypertension--beyond vasodilator therapy. N Engl J Med 1998, 338:321-322.
39. Wigley F.M., Wise R.A., Seibold J.R., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994, 120:199-206.
40. Wigley F.M., Korn J.H., Csuka M.E., et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998, 41:670-677.
41. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
42. Denton C.P., Humbert M., Rubin L., et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006, 65:1336-1340.
43. Korn J.H., Mayes M., Matucci Cerinic M., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985-3993.
44. Seibold J.R., Denton C.P., Furst D.E., et al. Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc). Arthritis Rheum 2005, 52:4057.
45. García de la Peña-Lefebvre P., Rodríguez Rubio S., Valero Expósito M., et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford) 2008, 47:464-466.
46. Tsifetaki N., Botzoris V., Alamanos Y., et al. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year follow-up study. J Rheumatol 2009, 36:1550-1552.
47. Selenko-Gebauer N., Duschek N., Minimair G., et al. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatology (Oxford) 2006, 45(Suppl. 3):iii45-iii48.
48. Hettema M.E., Zhang D., Bootsma H., et al. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 2007, 66:1398-1399.
49. Nguyen V.A., Eisendle K., Gruber I., et al. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford) 2010, 49:583-587.
50. Ambach A., Seo W., Bonnekoh B., et al. Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil. J Dtsch Dermatol Ges 2009, 7:888-891. [Article in English, German].
51. Denton C.P., Black C.M. Scleroderma and related disorders: therapeutic aspects. Baillieres Best Pract Res Clin Rheumatol 2000, 14:17-35.
52. Beckett V.L., Conn D.L., Fuster V., et al. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 1984, 27:1137-1143.
53. Denton C.P., Howell K., Stratton R.J., et al. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 2000, 18:499-502.
54. Lakshminarayanan S., Vázquez-Abad D., Maestrello S.J., et al. Treatment of severe Raynaud's phenomenon and ischemic ulcerations with tissue plasimogen activator. Clin Exp Rheumatol 1999, 17:260.
55. Goldberg J., Dlesk A. Successful treatment of Raynaud's phenomenon with pentoxifylline. Arthritis Rheum 1986, 29:1055-1056.
56. Wasserman A., Brahn E. Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomy. Semin Arthritis Rheum 2010, 40:137-146.
57. Tomaino M.M. Digital arterial occlusion in scleroderma: is there a role for digital arterial reconstruction?. J Hand Surg Br 2000, 25:611-613.
58. Bogoch E.R., Gross D.K. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 2005, 32:642-648.
59. Abou-Raya A., Abou-Raya S., Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008, 35:1801-1808.
60. Sunderkötter C., Herrgott I., Brückner C., et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009, 160:835-843.